Earnings ·
Mineralys reports Q3 net loss of $57.3M as it prepares for December PDUFA decision on lorundrostat
MLYSMineralys Therapeutics, Inc.
Mineralys Therapeutics reported a third-quarter net loss of $57.3 million, an increase from $36.9 million in the prior-year period, driven by higher general and administrative expenses related to commercialization preparations. Research and development expenses decreased to $22.7 million following the conclusion of pivotal trials. The company holds $624.7 million in cash and investments, sufficient to fund operations into 2028. Mineralys is advancing launch readiness for lorundrostat ahead of the December 22, 2026 PDUFA target date. Additionally, director Derek DiRocco resigned effective December 31, 2026. The company operates in the biopharmaceutical industry, developing medicines to treat hypertension and aldosterone-related comorbidities.